Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review
暂无分享,去创建一个
M. Port | C. Corot | S. Le Greneur | I. Raynal | J. Idee | M. Schaefer
[1] Lone Skov,et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.
[2] M. Tweedle,et al. Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.
[3] H. Ersoy,et al. Effects of gadopentetate dimeglumine and gadodiamide on serum calcium, magnesium, and creatinine measurements , 2006, Journal of magnetic resonance imaging : JMRI.
[4] V. Lorusso,et al. Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as 'sponges' of Gd3+ ions. , 2006, Contrast media & molecular imaging.
[5] Sandra F. Williams,et al. Spurious hypocalcemia after gadodiamide administration. , 2005, Mayo Clinic proceedings.
[6] P. Anelli,et al. Magnetic resonance contrast agents: from the bench to the patient. , 2005, Current pharmaceutical design.
[7] J. Mintorovitch,et al. Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths , 2005, Investigative radiology.
[8] T. Ishiguchi,et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. , 2005, Radiation medicine.
[9] T. Balzer,et al. Interference of Gadolinium-Containing Contrast-Enhancing Agents With Colorimetric Calcium Laboratory Testing , 2005, Investigative radiology.
[10] R. Oyen,et al. Artifactual hypocalcaemia after intravenous administration of gadodiamide (Omniscan). , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[11] R. Natesh,et al. Structure of angiotensin I-converting enzyme. , 2004, Cellular and molecular life sciences : CMLS.
[12] U. Eriksson,et al. What’s new in the renin-angiotensin system? , 2004, Cellular and Molecular Life Sciences CMLS.
[13] M. Hynes,et al. Measurement of serum calcium concentration after administration of gadoversetamide in dogs. , 2004, Radiology.
[14] G. Kost,et al. Spurious hypocalcemia after Omniscan- or OptiMARK-enhanced magnetic resonance imaging: an algorithm for minimizing a false-positive laboratory value. , 2004, Archives of pathology & laboratory medicine.
[15] G. R. Stevens,et al. Pharmacokinetics and Safety of the MRI Contrast Agent Gadoversetamide Injection (Optimark) in Healthy Pediatric Subjects , 2004, Investigative radiology.
[16] W. Gibby,et al. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy , 2004, Investigative radiology.
[17] L. V. Rao,et al. Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays. , 2004, American journal of clinical pathology.
[18] N. Abdou,et al. Safety assessment of gadoversetamide (OptiMARK®) administered by power injector , 2004, Journal of magnetic resonance imaging : JMRI.
[19] Pseudohypocalcemia after magnetic resonance imaging with gadolinium in patients with cirrhosis , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[20] C. Corot,et al. Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation , 1998, Biometals.
[21] M. Knopp,et al. More on pseudohypocalcemia and gadolinium-enhanced MRI. , 2004, The New England journal of medicine.
[22] V. Runge,et al. Contrast Agents for Magnetic Resonance Imaging: Safety Update , 2003, Topics in magnetic resonance imaging : TMRI.
[23] C. J. Doorenbos,et al. Severe pseudohypocalcemia after gadolinium-enhanced magnetic resonance angiography. , 2003, The New England journal of medicine.
[24] M. Bellin,et al. Currently used non-specific extracellular MR contrast media , 2003, European Radiology.
[25] K. Kent,et al. Gadodiamide administration causes spurious hypocalcemia. , 2003, Radiology.
[26] A. Turner. Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. , 2003, Biochemical Society transactions.
[27] B. Rogachev,et al. Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[28] Baker Rj. The effect of gadolinium-based MRI contrast agents on the biodistribution of 67Ga , 2002 .
[29] R. Baker. The effect of gadolinium-based MRI contrast agents on the biodistribution of 67Ga , 2002, Nuclear medicine communications.
[30] O. Wada,et al. Increased apoptosis in a variety of tissues of zinc-deficient rats. , 2001, Life sciences.
[31] M. Periasamy,et al. Toxicological Assessment of Gadoversetamide Injection (OptiMARK®), a New Contrast-Enhancement Agent for Use in Magnetic Resonance Imaging , 2001, Investigative radiology.
[32] S. Laurent,et al. Stability of MRI Paramagnetic Contrast Media: A Proton Relaxometric Protocol for Transmetallation Assessment , 2001, Investigative radiology.
[33] K Bensel,et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[34] C. Fierke,et al. Function and mechanism of zinc metalloenzymes. , 2000, The Journal of nutrition.
[35] W. Heindel,et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. , 2000, Investigative radiology.
[36] A. Pałasz,et al. Toxicological and cytophysiological aspects of lanthanides action. , 2000, Acta biochimica Polonica.
[37] M. Port,et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. , 1999, Journal of pharmaceutical and biomedical analysis.
[38] R. Lauffer,et al. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.
[39] H. Thomsen,et al. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.
[40] C. Corot,et al. Structure‐activity relationship of macrocyclic and linear gadolinium chelates: Investigation of transmetallation effect on the zinc‐dependent metallopeptidase angiotensin‐converting enzyme , 1998, Journal of magnetic resonance imaging : JMRI.
[41] Krishan Kumar. Macrocyclic polyamino carboxylate complexes of Gd(III) as magnetic resonance imaging contrast agents , 1997 .
[42] W. Gibby,et al. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. , 1996, Investigative radiology.
[43] J. Brunberg,et al. Adverse reactions to gadolinium contrast media: a review of 36 cases. , 1996, AJR. American journal of roentgenology.
[44] W. Gibby,et al. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. , 1996, Investigative radiology.
[45] G. Jackson,et al. Metal ion speciation in blood plasma: gallium-67-citrate and MRI contrast agents. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[46] H. Hakusui,et al. Pharmacokinetics and stability of caldiamide sodium in rats. , 1996, Arzneimittel-Forschung.
[47] P. Normann,et al. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. , 1995, Scandinavian journal of clinical and laboratory investigation.
[48] P. Wedeking,et al. Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.
[49] H. Weinmann,et al. Pharmacokinetics, Dose Proportionality, and Tolerability of Gadobutrol after Single Intravenous Injection in Healthy Volunteers , 1994, Investigative radiology.
[50] E. Holtz,et al. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. , 1993, Investigative radiology.
[51] J. S. Mann,et al. Stability of Gadolinium Complexes In Vitro and In Vivo , 1993, Journal of computer assisted tomography.
[52] N. Obuchowski,et al. 3D MRI of the cervical spine: low flip angle FISP vs. Gd-DTPA TurboFLASH in degenerative disk disease. , 1993, Journal of computer assisted tomography.
[53] A. Nordenbo,et al. Acute deterioration of myasthenia gravis after intravenous administration of gadolinium-DTPA , 1992, The Lancet.
[54] M. Tweedle,et al. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. , 1992, Investigative radiology.
[55] C. Higgins,et al. Amelioration of cardiodepressive effects of gadopentetate dimeglumine with addition of ionic calcium. , 1992, Radiology.
[56] W. Matthai,et al. Comparative Safety of High‐Osmolality and Low‐Osmolality Radiographic Contrast Agents: Peport of a Multidisciplinary Working Group , 1992, Investigative radiology.
[57] P. Wedeking,et al. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. , 1992, Magnetic resonance imaging.
[58] S. Quay,et al. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. , 1991, Investigative radiology.
[59] H. Weinmann,et al. Gallium-67/stable gadolinium antagonism. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[60] H. Niendorf,et al. Tolerance data of Gd-DTPA: a review. , 1991, European journal of radiology.
[61] J. Hagan,et al. Reaction of gadolinium chelates with endogenously available ions. , 1991, Magnetic resonance imaging.
[62] D. White,et al. Gallium-67/stable gadolinium antagonism: MRI contrast agent markedly alters the normal biodistribution of gallium-67. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[63] B. Biagi,et al. Gadolinium blocks low- and high-threshold calcium currents in pituitary cells. , 1990, The American journal of physiology.
[64] B. Bonnemain,et al. Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. , 1990, Investigative radiology.
[65] J. Lansman. Blockade of current through single calcium channels by trivalent lanthanide cations. Effect of ionic radius on the rates of ion entry and exit , 1990, The Journal of general physiology.
[66] W. Cacheris,et al. The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.
[67] H. Niendorf,et al. Serum iron and serum bilirubin after administration of Gd-DTPA-dimeglumine. A pharmacologic study in healthy volunteers. , 1988 .
[68] J. Wittenberg,et al. Gd-DOTA: characterization of a new paramagnetic complex. , 1988, Radiology.
[69] P. Wedeking,et al. Comparison of the biodistribution of 153Gd-labeled Gd(DTPA)2-, Gd(DOTA)-, and Gd(acetate)n in mice. , 1988, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[70] E. Roux,et al. Contrast agents in magnetic resonance imaging. , 1988, Journal belge de radiologie.
[71] A. Prasad. Clinical manifestations of zinc deficiency. , 1985, Annual review of nutrition.
[72] N. Itoh,et al. Characterization of Gd3+ and Tb3+ binding sites on Ca2+,Mg2+-adenosine triphosphatase of sarcoplasmic reticulum. , 1984, Journal of biochemistry.
[73] J. C. Smith,et al. Testicular damage associated with zinc deficiency in pre- and postpubertal rats: response to zinc repletion. , 1982, The Journal of nutrition.
[74] Á. Párducz,et al. Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride. , 1980, British journal of experimental pathology.
[75] L. Hurley,et al. Severe zinc deficiency in male and female rats. , 1968, The Journal of nutrition.